ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 176 filers reported holding ASCENDIS PHARMA A/S in Q4 2020. The put-call ratio across all filers is 1.39 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $351,000 | +33.0% | 2,993 | +52.5% | 0.02% | +36.4% |
| Q4 2021 | $264,000 | -41.2% | 1,963 | -30.4% | 0.01% | -50.0% |
| Q3 2021 | $449,000 | +44.4% | 2,819 | +19.1% | 0.02% | +37.5% |
| Q2 2021 | $311,000 | +5.8% | 2,367 | +3.7% | 0.02% | -5.9% |
| Q1 2021 | $294,000 | -7.5% | 2,282 | +19.9% | 0.02% | -22.7% |
| Q4 2020 | $318,000 | -17.6% | 1,904 | -23.9% | 0.02% | -85.1% |
| Q3 2020 | $386,000 | +0.8% | 2,503 | -3.4% | 0.15% | +335.3% |
| Q2 2020 | $383,000 | +23.5% | 2,590 | -6.0% | 0.03% | +3.0% |
| Q1 2020 | $310,000 | -32.2% | 2,755 | -16.1% | 0.03% | -5.7% |
| Q4 2019 | $457,000 | – | 3,282 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |